DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/mfsgz3/p53_signaling) has announced the addition of the "p53 Signaling Pathway in Cancer Drug Pipeline Update 2015" report to their offering.
p53 activation is induced by a number of stress signals, including DNA damage, oxidative stress and activated oncogenes. The p53 protein is employed as a transcriptional activator of p53-regulated genes. This results in three major outputs; cell cycle arrest, cellular senescence or apoptosis. Other p53-regulated gene functions communicate with adjacent cells, repair the damaged DNA or set up positive and negative feedback loops that enhance or attenuate the functions of the p53 protein and integrate these stress responses with other signal transduction pathways.
There are today 96 companies plus partners developing 79 p53 signaling pathway targeting drugs in 266 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 67 drugs. P53 Signaling Pathway In Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 76 different targets.
All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 75 out of the 75 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.
All drugs targets are further categorized on in the software application by 32 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed - 2
- Pre-registration - 1
- Phase III - 5
- Phase II - 25
- Phase I - 36
- Preclinical - 59
- No Data - 2
- Suspended - 1
-
Ceased - 67
Delivery Format: Desktop App plus Online Access to Updates (One Year)
For more information visit http://www.researchandmarkets.com/research/mfsgz3/p53_signaling
